Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The spread of molecular markers of artemisinin partial resistance and diagnostic evasion in Eritrea: a retrospective molecular epidemiology study.

The Lancet. Microbe - 1 Feb 2025

Mihreteab Selam, Anderson Karen, Fuente Irene Molina de la, Sutherland Colin J, Smith David, Cunningham Jane, Beshir Khalid B, Cheng Qin

Abstract excerpt

BACKGROUND: Eritrea was the first African country to discontinue the use of histidine rich protein 2 (HRP2)-detecting rapid diagnostic tests (RDTs) for malaria diagnosis following reports of a high prevalence of pfhrp2/3-deleted Plasmodium falciparum parasites causing false-negative results in the country. Eritrea was also the first African country to report partial artemisinin resistance due to the P falciparum...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leprosy Research and Treatment
Share to Malaria Research and Control

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Parasites and Host Interactions

Source

Open in PubMed Open full text

Identifiers

PMID: 39653047
DOI: 10.1016/S2666-5247(24)00172-1
PMCID: PMC11798904

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The spread of molecular markers of artemisinin partial resistance and diagnostic evasion in Eritrea: a retrospective molecular epidemiology studyPMID 39653047Read ↗

Prevalence of PfKelch13 Mutations and Clinical Indicators of Artemisinin Partial Resistance in Africa: A Systematic Review and Meta-Analysis of Observational CohortsSemantic proximity Read ↗

Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in EritreaSemantic proximity Read ↗

Understanding the Global Spread of Artemisinin Resistance: Insights from over 100K <i>Plasmodium falciparum</i> SamplesSemantic proximity Read ↗

Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda.Semantic proximity Read ↗

Emerging threat of Partial Artemisinin Resistance Markers in P. falciparum Parasite Populations in multiple geographical locations in high Transmission Regions of UgandaSemantic proximity Read ↗

High prevalence and emerging positive association of kelch13 R622I and HRP2-based RDT negativity in Plasmodium falciparum in northern Ethiopia.Semantic proximity Read ↗

Expansion of Artemisinin Partial Resistance Mutations and Lack of Histidine Rich Protein-2 and -3 Deletions in<i>Plasmodium falciparum infections</i>from Rukara, RwandaSemantic proximity Read ↗

Molecular surveillance of pfhrp2 and pfhrp3 deletions in Plasmodium falciparum isolates from MozambiqueSemantic proximity Read ↗

Clonal spread of<i>Plasmodium falciparum</i>candidate artemisinin partial resistance<i>Kelch13</i>622I mutation and co-occurrence with<i>pfhrp2/3</i>deletions in EthiopiaSemantic proximity Read ↗

Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in EthiopiaSemantic proximity Read ↗

Artemisinin resistant <i>kelch13</i> R622I and RDT negativity approaching predominance in northern Ethiopia and emerging C580Y of African origin threaten falciparum malaria controlSemantic proximity Read ↗

Clonal Transmission of Emerging Novel <i>Plasmodium falciparum</i> Kelch13 Mutations and Increasing Complexity of Infection in Libreville, Gabon, 2021-2023Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.